|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-4-4
|
|
pubmed:abstractText |
There is little established information regarding the safety of antitumor necrosis factor therapies used outside the setting of clinical trials. This study evaluated the long-term safety and tolerability of open-label use of etanercept when used to treat patients with a variety of systemic rheumatic diseases. Reduction of concomitant corticosteroid and disease-modifying antirheumatic drug was also assessed.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
17-21
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11932873-Academic Medical Centers,
pubmed-meshheading:11932873-Antirheumatic Agents,
pubmed-meshheading:11932873-Female,
pubmed-meshheading:11932873-Humans,
pubmed-meshheading:11932873-Immunoglobulin G,
pubmed-meshheading:11932873-Immunologic Factors,
pubmed-meshheading:11932873-Infection,
pubmed-meshheading:11932873-Male,
pubmed-meshheading:11932873-Massachusetts,
pubmed-meshheading:11932873-Methotrexate,
pubmed-meshheading:11932873-Middle Aged,
pubmed-meshheading:11932873-Prednisone,
pubmed-meshheading:11932873-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:11932873-Rheumatic Diseases
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Experience with etanercept in an academic medical center: are infection rates increased?
|
|
pubmed:affiliation |
Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Diseases Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
